We anticipate that the sales and pipeline progression made by Newron in 2016 will be cemented further in 2017/18. A critical catalyst remains the US Xadago (Parkinson’s disease (PD) therapy) approval which is imminent (revised PDUFA date is 21 March); this will materially impact the share price performance. We anticipate US launch in H217 by sub licensee, US WorldMeds. Data from pipeline assets sarizotan (Rett’s syndrome, RS) and evenamide (schizophrenia) in the upcoming 18 months
13 Mar 2017
Marching into 2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Marching into 2017
Newron Pharmaceuticals S.p.A. (NWRN:SWX) | 0 0 0.0%
- Published:
13 Mar 2017 -
Author:
Dr Susie Jana -
Pages:
7
We anticipate that the sales and pipeline progression made by Newron in 2016 will be cemented further in 2017/18. A critical catalyst remains the US Xadago (Parkinson’s disease (PD) therapy) approval which is imminent (revised PDUFA date is 21 March); this will materially impact the share price performance. We anticipate US launch in H217 by sub licensee, US WorldMeds. Data from pipeline assets sarizotan (Rett’s syndrome, RS) and evenamide (schizophrenia) in the upcoming 18 months